藥學系碩士班

110 學年度		
最低修業年限	一年	
應修學分數	24 學分(不含論文)	
	本系碩士班下設藥物科技組(Division of Pharmaceutical Sciences), 臨床藥學組 (Division of Clinical Pharmacy), 社會與管理藥學組(Division of Social and Administrative Pharmacy)。	
	一、必修科目: 1.藥物科技組: 藥物科技研究方法(英文)、進階藥物科學(英文)、應用藥物科學(英文)、「專題討論」 (四學分)及學術研究倫理 藥理學(一)、分子生物學、生物藥學通論、生物藥學通論(英文)(四選一) 藥理學(二)、細胞生物學、生物藥學持論、轉譯生物藥學的實際應用(英文)(四選一) 2.臨床藥學組: 用藥安全與醫藥政策特論、高等藥物治療學、細胞色素 P450 藥物代謝特論、臨床藥學專科實習(一)、臨床藥學專科實習(二)、藥物基因體學與臨床應用、、「專題討論」(四學分,109學年入學之臨床藥學組學生須修畢臨床藥學專題討論四學分)及學術研究倫理。 3.社會與管理藥學組: 衛生行政與健康保險、藥物流行病學、健康資料分析與應用、藥事經濟學、「專題 計學、(四學公)及學術研究	
	討論」(四學分)及學術研究倫理。 二、畢業資格: 1.修畢必修及必選科目且須修滿至少24 學分。 2.論文進度報告 (1)本系碩士班於第一學年度第二學期結束前舉行碩士論文計畫書報告,由本系專、兼任老師評定及格與否。 (2)本系碩士班於第二學年度第一學期結束前舉行第一次論文進度報告,以學位考形式邀請口試委員參加評分。 (3)本系碩士班於第二學年第二學期舉行第二次論文進度報告,以論文口試為主體,由本系專、兼任老師評定及格與否。 (4)至少通過一次進度報告得參與學位考試。 3.通過論文口試。	

其他未盡事宜,依據本系碩士班研究生修業規章辦理。

備註

Master Program of the Department of Pharmacy Academic Year 2021

Minimum Term of Study	One year
Minimum Credits	24 credits
Minimum Credits	
	2. Graduation requirements:(1) Completion of at least 24 credit hours of required and elective courses.(2) Research progress reports:

	 Each student must write and present a thesis proposal before the end of the Spring Semester of the first academic year. The full-time and/or the adjunct faculty members will participate in the grading (Pass/No Pass). Each student must write and present the first research progress report before the end of the Fall Semester of the second academic year. The progress report will be examined by the student's Advisory Committee. Each student must complete the second research progress report (written and oral presentation) in the Spring Semester of the second academic year. As a qualifying exam, the oral presentation will be examined by the full-time and adjunct faculty members. (3) Each student must complete and pass the final oral examination for the Master's thesis.
Notes	Any other outstanding issues will be handled by relevant regulations. If there were any discrepancy between the Chinese version and the English version, the original Chinese version shall prevail.